4. MOVe-OUT trial
Jayk Bernal A, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med.
https://doi.org/10.1056/NEJMoa2116044.
12. −10
−20 10
0 20
Placebo Better
Molnupiravir Better
Sex
Female
Male
Days since onset of symptoms
≤3
>3
Baseline Covid-19 severity
Mild
Moderate
Baseline SARS-CoV-2 nucleocapsid antibody status
Positive
Negative
Risk factors for severe Covid-19
>60 yr of age
Obese
Diabetes mellitus
Serious heart condition
Race
American Indian or Native American
Asian
Black
White
Baseline SARS-CoV-2 qualitative assay
Detectable
Undetectable
Unknown
Absolute Risk Reduction (95% CI)
Subgroup Molnupiravir Placebo
16/379
32/330
25/339
23/370
19/395
29/311
5/136
39/541
12/118
29/535
17/107
8/86
18/207
7/25
10/157
29/556
45/614
0/54
3/41
27/344
41/355
28/335
40/364
27/376
40/321
2/146
64/520
16/127
46/507
17/117
9/78
21/199
7/23
15/142
54/573
61/613
0/51
7/35
no. of events/no. of participants percentage points
−30
−3.6 (−7.4 to −0.2)
−1.9 (−6.5 to 2.8)
−1.0 (−5.2 to 3.2)
−4.8 (−9.0 to −0.7)
−2.4 (−5.9 to 1.0)
−3.1 (−8.1 to 1.8)
2.3 (−1.7 to 7.1)
−5.1 (−8.8 to −1.6)
−2.4 (−10.6 to 5.8)
−3.7 (−6.9 to −0.5)
1.4 (−8.2 to 11.1)
−2.2 (−12.4 to 7.5)
−1.9 (−7.8 to 4.0)
−2.4 (not calculated)
−4.2 (−11.1 to 2.2)
−4.2 (−7.3 to −1.2)
−2.6 (−5.8 to 0.5)
0.0 (−7.1 to 6.7)
−12.7 (−29.9 to 2.9)
SARS-CoV-2抗体陽性(既感染)者では
プラセボ群の重症化リスクが低いため差がない
Jayk Bernal A, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med.
https://doi.org/10.1056/NEJMoa2116044.
13. • 中間解析の時点で有効性が確認されたものとして臨床
試験としてはこの時点で終了
• 中間解析の時点で,入院または死亡の相対リスク
50%低下→最終的には30%低下に
• 中間解析以降の組み入れ集団でモルヌピラビル群のイ
ベント発生はほぼ変わらないが,プラセボ群のイベン
ト発生が減ったことが大きい(中間解析以降の組み入
れ集団は女性,既感染,ベースラインでウイルス量低
値がプラセボ群で少しずつ多かったことが原因か?)
Jayk Bernal A, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med.
https://doi.org/10.1056/NEJMoa2116044.
14. モルヌピラビル 副作用
• 下痢,悪心,浮動性めまい,頭痛:1~5%
• 嘔吐,発疹,蕁麻疹:1%未満
• 中毒性皮疹:頻度不明
• 臨床試験で有害事象の発生はプラセボと大差なし
Jayk Bernal A, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med.
https://doi.org/10.1056/NEJMoa2116044.
ラゲブリオ®カプセル200mg 添付文書
20. EPIC-HR trial
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVIDTM
https://www.fda.gov/media/155050/download (accessed December 27, 2021).
25. 有害事象(安全性解析集団)
イベント
ソトロビマブ
N=430
プラセボ
N=438
何らかの有害事象 73 (17%) 85 (19%)
重篤な有害事象 7 (2%) 26 (6%)
infusion reaction 6 5
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early Treatment for
Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med 2021;385:1941‒50.